The availability of TRK inhibitors as a targeted therapy for patients with an NTRK gene fusion tumor has enabled physicians to optimize treatment strategies in these patients, with the potential to improve outcomes and quality of life [44–47]. Here, TPM3 is linked to neoplasm.